In this early proof-of-concept study, Dr. Koichi Takahashi from MD Anderson uses the newly available Tapestri Platform for high-throughput single-cell DNA sequencing of acute myeloid leukemia (AML) tumors. Sophisticated microfluidics and droplet technology allow researchers to encapsulate individual cells into droplets and enhance previous low-throughput single-cell technologies that relied on microwells to encapsulate single cells. In his presentation, Dr. Takahashi shows tantalizing data that comes when single nucleotide variants (SNVs) are uncovered on a per-cell basis. These data allow for the clonality of the sample to be uncovered instead of being inferred from bulk sequencing technologies. In addition, rare clones containing multiple co-occurring mutations are detected at a sensitivity of 0.1%
